Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1984 2022-06-08 02:21:30 |
2 format correct -28 word(s) 1956 2022-06-08 02:34:55 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Farr, K. High-Risk Groups Relevant for PDAC Early Detection. Encyclopedia. Available online: https://encyclopedia.pub/entry/23804 (accessed on 14 June 2024).
Farr K. High-Risk Groups Relevant for PDAC Early Detection. Encyclopedia. Available at: https://encyclopedia.pub/entry/23804. Accessed June 14, 2024.
Farr, Katherina. "High-Risk Groups Relevant for PDAC Early Detection" Encyclopedia, https://encyclopedia.pub/entry/23804 (accessed June 14, 2024).
Farr, K. (2022, June 08). High-Risk Groups Relevant for PDAC Early Detection. In Encyclopedia. https://encyclopedia.pub/entry/23804
Farr, Katherina. "High-Risk Groups Relevant for PDAC Early Detection." Encyclopedia. Web. 08 June, 2022.
High-Risk Groups Relevant for PDAC Early Detection
Edit

Pancreatic cancer, one of the most lethal malignancies, is increasing in incidence. While survival rates for many cancers have improved dramatically, people with pancreatic cancer have persistently poor outcomes. Potential cure for pancreatic cancer involves surgical resection and adjuvant therapy. However, approximately 85% of patients diagnosed with pancreatic cancer are not suitable for potentially curative therapy due to locally advanced or metastatic disease stage. Because of this stark survival contrast, any improvement in early detection would likely significantly improve survival of patients with pancreatic cancer through earlier intervention.

pancreatic cancer pancreatic ductal adenocarcinoma early detection high-risk groups

1. High-Risk Groups Relevant for PDAC Early Detection

Patients with cystic lesions are at increased risk for developing Pancreatic ductal adenocarcinoma (PDAC) [1]. There are several risk factors for developing a cystic precursor lesion and associated PDAC. The relationship of diabetes mellitus and PDAC is an intense area of research interest, with significant progress being made in interactions of diabetes and PDAC development [2]. Further, patients with chronic pancreatitis are at an increased risk of developing a cystic precursor lesion and associated PDAC [3]. Certain genetic syndromes and a familial PDAC have been shown to pose a risk [4]. Based on the literature, these patients with pancreatic cystic lesions, high-risk individuals with a familial PDAC risk, at risk cohorts with pancreatitis, genetic syndromes and germline mutations, and elderly patients with new-onset diabetes will be focused (Table 1).
Table 1. High risk criteria for PDAC.

2. Familial PDAC

A family history of pancreatic cancer is observed in 5% to 10% of patients with PDAC. Gene mutations in CDKN2A (p16), BRCA2, and PALB2 are associated with PDAC [5][6][7][8]. Familial PDAC is defined as having two or more first-degree relatives with PDAC. The relative risk for PDAC is 2.41 in sporadic cases (i.e., families with only one relative with PDAC or with multiple PDACs in more distant relatives and/or spouses with PDAC), whereas the risk increases to 6.79 and 17.2 times in cases with two and more first-degree relatives with PDAC, respectively [9]. In the familial PDAC kindreds, risk varied by the number of first-degree relatives with PDAC, such that risk was higher in individuals with three first-degree relatives who had PDAC (Standardized Incidence Ratio, SIR = 17.02; 95% CI = 7.34 to 33.5; p < 0.01), but lower in individuals who had two first-degree relatives with PDAC (SIR = 3.97, 95%CI = 1.59 to 8.2, p = 0.05) or with one affected first-degree relative (SIR = 6.86, 95% CI = 3.75 to 11.04, p < 0.001) [10]. Whereas risk was higher for familial PDAC kindred members who had one first-degree relative with PDACs compared with two, the confidence intervals for these two estimates largely overlap. Moreover, a higher risk of PDAC has been observed among familial pancreatic cancer kindreds with younger-onset PDAC (age, <50 years; standardized incidence ratio = 9.3%) [11]. A familial history of pancreatic cancer suggests a high risk for PDAC, and the incidence of PDAC depends on the number of first-degree relative with PDAC. Identification of a family history of PDAC is therefore, important.

3. Inherited Cancer Predisposition Syndromes

Several cancer predisposition syndromes are known to increase PDAC risk (Table 1) [12][13]. Although genetic defects likely remain unknown, several genetic syndromes associated with PDAC have been discovered. The inherited cancer syndromes, such as hereditary breast-ovarian cancer syndrome, hereditary pancreatitis, Peutz–Jeghers syndrome, familial atypical multiple mole myeloma, Lynch syndrome, Li–Fraumeni syndrome, familial breast-ovarian cancer with, and hereditary nonpolyposis colorectal cancer have all been associated with increased risk of developing PDAC [14][15][16][17][18]. However, because of their rarity, they in total account for only a small fraction of PDACs.

4. Pancreatic Cystic Lesions

Pancreatic cystic lesions can be divided into three main types: inflammatory, serous and mucinous, as well as other rare cyst types. For the scope of these content, mucinous cystic lesions are described as precursor lesions, harbouring a greater potential for malignancy. It is now well-known that most PDAC originate from microscopic pancreatic intraepithelial neoplasia (PanIN) and macroscopic precursor lesions. PanIN refers to microscopic, intraductal neoplasms (by definition <5 mm) lined by gastric–foveolar epithelia of varying degrees of architectural and cytologic atypia. These cannot be detected by current imaging modalities. While PanINs contribute to most of PDACs, a significant proportion of PDACs arise from macroscopic mucinous neoplasms, such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) (Figure 1). These cystic precursor lesions share many genetic alterations found in PDACs. Up to 15% of PDACs are thought to arise from mucinous pancreatic cysts, which include IPMNs and MCN [19]. The incidence of PDAC was reported to be 2% in 349 patients with IPMN who were observed for 3.7 years [20]. Another study reported that PDAC occurred in 5 of 60 (8%) patients with IPMN (with a diameter <10 mm), who were observed for 87 months, and the 1- and 5-year mortality rates were 1.1% and 6.9%, respectively [21]. The presence of any pancreatic cyst, including IPMN, was reported to be a high-risk factor for PDAC development, accounting for 0.95% of patients with pancreatic cysts per 1 year, which was 22.5 times higher than that in individuals without pancreatic cystic lesions [22]. Patients harbouring a cystic lesion are more likely to progress to cancer than even those with family history of PDAC making them the prime target population for screening and surveillance modalities [11]. However, the matter is complicated by cystic lesions presenting a variable risk of malignant transformation (Figure 1).
Figure 1. Transformation in IPNM on MRI and CT. From left to right- Diffusion weighted imaging, T2, post contrast T1 and CT images in the same patient. Top row shows a simple cystic lesion consistent with a side branch IPMN, showing no malignant features. Bottom row shows a cystic lesion displaying solid enhancing components with restricted diffusion, consistent with malignant degeneration within an IMPN. Arrows indicate cystic component with no cancer (top), and with cancer (bottom).
IPMNs are macroscopic (>1 cm by definition) cystic tumours characterised by intraductal growth of papillary lesions with typically copious and thick mucin production. IPMNs commonly originate from the main pancreatic duct, its contributing branches, or possible mixed origin. They are more common in elderly men (>65 years). Most patients with IPMNs are asymptomatic; some patients may have nonspecific symptoms of abdominal pain, jaundice, as well as symptoms due to exocrine and/or endocrine pancreatic insufficiency. The pathologic nomenclature of IPMNs is complex and evolving. The incidence and type of invasive malignancy developing in IPMNs differ from one histologic type to another. Pancreatic ductal communication is the key feature differentiating these from other cystic neoplasms. Main duct IPMN is characterized by cystic dilatation of the main duct, variable ductal wall thickening, and thick, abundant mucin that distends and obstructs the duct (Figure 2). Main duct IPMN have a higher predisposition for malignant transformation, compared with branch duct IPMNs. A longitudinal study by Levy et al. demonstrated the 5-year actuarial risk of progression to high-grade dysplasia among main duct IPMNs was 63%, while 15% in the branch duct IPMNs [20]. Patients with an IPMN are at an increased risk for developing not only IPMN-associated PDAC but also PDAC independent from the IPMN, concomitant carcinomas [19]. Existing guidelines recommend immediate surgical resection for any lesion with high-risk stigmata and regular surveillance with interval imaging for all mucinous or indeterminate lesions [23]. Surveillance protocols vary between the different guidelines [24].
Figure 2. Characteristics of pancreatic cystic lesion types and their key differences. IPMN= intraductal papillary mucinous neoplasms; MCN= mucinous cystic neoplasms.
Mucinous cystic neoplasms, the least common macroscopic precursor lesion, differ from IPMNs in that they do not communicate with the ductal system, and they are almost always solitary. In addition, 98% of mucinous cystic neoplasms occur in perimenopausal women with a distinct proclivity to involve the distal pancreas (>90% occur in the tail region) and histologically characterised by a pathognomonic spindle cell ovarian-type stroma. Surgical resection is recommended in mucinous cystic neoplasms of greater than 4 cm, symptomatic tumours, and enhancing mural nodules. European evidence-based guidelines suggest that asymptomatic or smaller mucinous cystic neoplasms without suspicious features need long-term surveillance (every 6 months for 1st year and then annual) as long as they do not have surgical contraindications [25]. The risk of malignant transformation of mucinous cystic neoplasms is lower than that of IPMN; approximately 16% of mucinous cystic neoplasms are associated with invasive malignancy. When malignancy develops, it is typically of the tubular carcinoma variant of PDAC, but lymph node metastasis is usually not seen.

5. Newly Onset Diabetes Mellitus

Although the association between diabetes mellitus and PDAC has been known since 1800s, the intricate relationship between the two conditions has yet to be fully understood. Diabetes appears to have a multidirectional association with PDAC. The onset of diabetes has been shown to precede occurrence of PDAC by a few years and resolve after the resection [26]. The mechanism can be attributed to paraneoplastic phenomenon, leading to induced insulin resistance from pancreatic polypeptide deficiency. Although long standing type 2 diabetes is a modest risk factor (1.5–2-fold increased risk) for PDAC, newly onset diabetes may be a manifestation of PDAC [27]. It has been suggested that up to 85% of pancreatic cancer patients have diabetes or hyperglycaemia which can manifest 2–3 years before the development of PDAC [27]. This has been attributed to growth stimulation by endogenous hyperinsulinemia. Increased risks due to obesity and metabolic syndrome are also thought to arise from elevated insulin levels. For this newly identified high-risk group, there are no established guidelines or screening programs. Increasing epidemiological, clinical, and experimental evidence that newly onset diabetes is a clinical manifestation of asymptomatic PDAC provides hope for the early detection of PDAC in patients with diabetes.

6. Pancreatitis

Acute pancreatitis can be the initial clinical presentation of PDAC and can precede the diagnosis of PDAC by several weeks or months [28]. Few studies have reported a detailed list of the aetiology of acute pancreatitis in their study cohort [29][30][31][32]. Estimated 1.7–3.6% of patients with acute pancreatitis were finally diagnosed with PDAC. The pooled average was 2.03% in 2945 patients in these studies [28]. Duell et al. reported a nearly seven-fold increased relative risk for pancreatic cancer in individuals with a history of pancreatitis (adjusted odds ratio, 6.9; 95% CI, 3.4–14.1) [33]. Another study reported that 1.45% of patients with acute pancreatitis developed PDAC within the 2-year period, and the incidence of PDAC reduced in the third year; further, age 40 years and older was an added risk factor for PDAC [34]. Cases of carcinoma in situ were recently reported to be the cause of acute pancreatitis [35]. Acute pancreatitis can be an indicator of PDAC, and patients with acute pancreatitis should be observed for 2 years using diagnostic imaging techniques [28]. In chronic pancreatitis, >2-year observation showed that the relative risk for PDAC was 16.5 to 26.7, and the incidence ratios of PDAC occurrence were reported to be 1.1%, 1.8%, and 4.0% in 5-, 10- and 20-year observations, respectively [36]. Hereditary pancreatitis is defined by the following: acute recurrent pancreatitis or chronic pancreatitis in two and more members of a family; an absence of a history of alcohol abuse in at least one patient; and pancreatitis in at least one brother or sister younger than 40 years. If the patient has a p.R122H or p.N291 mutation on PRSS1, the diagnosis of hereditary pancreatitis is confirmed, irrespective of the definition. In hereditary pancreatitis, cumulative lifetime risk of PDAC is 40% [37]. The proportions of patients developing PDAC due to hereditary pancreatitis are 10%, 18.7%, and 53.5% in 50-, 60-, and 75-year-old patients, respectively [37]. Familial history of pancreatitis should be considered when examining a patient with pancreatitis.

References

  1. Carmicheal, J.; Patel, A.; Dalal, V.; Atri, P.; Dhaliwal, A.S.; Wittel, U.A.; Malafa, M.P.; Talmon, G.; Swanson, B.J.; Singh, S.; et al. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Biochim. Biophys. Acta 2019, 1873, 188318.
  2. Andersen, D.K.; Korc, M.; Petersen, G.M.; Eibl, G.; Li, D.; Rickels, M.R.; Chari, S.T.; Abbruzzese, J.L. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes 2017, 66, 1103–1110.
  3. Hao, L.; Zeng, X.-P.; Xin, L.; Wang, D.; Pan, J.; Bi, Y.-W.; Ji, J.-T.; Du, T.-T.; Lin, J.-H.; Zhang, D.; et al. Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients. Dig. Liver Dis. 2017, 49, 1249–1256.
  4. Goggins, M.; Overbeek, K.A.; Brand, R.; Syngal, S.; Del Chiaro, M.; Bartsch, D.K.; Bassi, C.; Carrato, A.; Farrell, J.; Fishman, E.K.; et al. Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2019, 69, 7–17.
  5. Hahn, S.A.; Greenhalf, B.; Ellis, I.; Sina-Frey, M.; Rieder, H.; Korte, B.; Gerdes, B.; Kress, R.; Ziegler, A.; Raeburn, J.A.; et al. BRCA2 Germline Mutations in Familial Pancreatic Carcinoma. JNCI J. Natl. Cancer Inst. 2003, 95, 214–221.
  6. Slater, E.P.; Langer, P.; Niemczyk, E.; Strauch, K.; Butler, J.; Habbe, N.; Neoptolemos, J.; Greenhalf, W.; Bartsch, D. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 2010, 78, 490–494.
  7. Mukherjee, B.; DeLancey, J.O.; Raskin, L.; Everett, J.; Jeter, J.; Begg, C.B.; Orlow, I.; Berwick, M.; Armstrong, B.K.; Kricker, A.; et al. Risk of Non-Melanoma Cancers in First-Degree Relatives of CDKN2A Mutation Carriers. JNCI J. Natl. Cancer Inst. 2012, 104, 953–956.
  8. Hu, C.; Hart, S.N.; Polley, E.C.; Gnanaolivu, R.; Shimelis, H.; Lee, K.Y.; Lilyquist, J.; Na, J.; Moore, R.; Antwi, S.O.; et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 2018, 319, 2401–2409.
  9. Fernandez, E.; La Vecchia, C.; D’Avanzo, B.; Negri, E.; Franceschi, S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 1994, 3, 209–212.
  10. Brune, K.A.; Lau, B.; Palmisano, E.; Canto, M.; Goggins, M.G.; Hruban, R.H.; Klein, A.P. Importance of Age of Onset in Pancreatic Cancer Kindreds. JNCI J. Natl. Cancer Inst. 2010, 102, 119–126.
  11. Mukewar, S.S.; Sharma, A.; Phillip, N.; Gupta, R.; Aryal-Khanal, A.; de Pretis, N.; Anani, V.; Enders, F.T.; Larson, J.J.; Takahashi, N.; et al. Risk of Pancreatic Cancer in Patients With Pancreatic Cysts and Family History of Pancreatic Cancer. Clin. Gastroenterol. Hepatol. 2018, 16, 1123–1130.e1.
  12. Hruban, R.H.; Canto, M.I.; Goggins, M.; Schulick, R.; Klein, A.P. Update on Familial Pancreatic Cancer. Adv. Surg. 2010, 44, 293–311.
  13. Klein, A.P. Genetic susceptibility to pancreatic cancer. Mol. Carcinog. 2011, 51, 14–24.
  14. Goldstein, A.M.; Chan, M.; Harland, M.; Hayward, N.K.; Demenais, F.; Bishop, D.T.; Azizi, E.; Bergman, W.; Scarrà, G.B.; Bruno, W.; et al. Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J. Med. Genet. 2006, 44, 99–106.
  15. Vasen, H.F.; A Gruis, N.; Frants, R.R.; A Van Der Velden, P.; Hille, E.T.; Bergman, W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer 2000, 87, 809–811.
  16. Van Asperen, C.J.; Brohet, R.M.; Meijers-Heijboer, E.J.; Hoogerbrugge, N.; Verhoef, S.; A Vasen, H.F.; Ausems, M.G.E.M.; Menko, F.H.; Garcia, E.B.G.; Klijn, J.G.M.; et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J. Med. Genet. 2005, 42, 711–719.
  17. Moran, A.; O’Hara, C.; Khan, S.; Shack, L.; Woodward, E.R.; Maher, E.; Lalloo, F.; Evans, D.G.R. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer 2012, 11, 235–242.
  18. Kastrinos, F.; Mukherjee, B.; Tayob, N.; Wang, F.; Sparr, J.; Raymond, V.M.; Bandipalliam, P.; Stoffel, E.M.; Gruber, S.B.; Syngal, S. Risk of Pancreatic Cancer in Families With Lynch Syndrome. JAMA 2009, 302, 1790–1795.
  19. Hruban, R.H.; Takaori, K.; Klimstra, D.S.; Adsay, V.; Albores-Saavedra, J.; Biankin, A.; A Biankin, S.; Compton, C.; Fukushima, N.; Furukawa, T.; et al. An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. Am. J. Surg. Pathol. 2004, 28, 977–987.
  20. Lévy, P.; Jouannaud, V.; O’Toole, D.; Couvelard, A.; Vullierme, M.P.; Palazzo, L.; Aubert, A.; Ponsot, P.; Sauvanet, A.; Maire, F. Natural History of Intraductal Papillary Mucinous Tumors of the Pancreas: Actuarial Risk of Malignancy. Clin. Gastroenterol. Hepatol. 2006, 4, 460–468.
  21. Kim, T.H.; Song, T.J.; Hwang, J.-H.; Yoo, K.-S.; Lee, W.-J.; Lee, K.-H.; Dong, S.-H.; Park, C.-H.; Park, E.-T.; Moon, J.H.; et al. Predictors of malignancy in pure branch duct type intraductal papillary mucinous neoplasm of the pancreas: A nationwide multicenter study. Pancreatology 2015, 15, 405–410.
  22. Canto, M.I.; Hruban, R.H.; Fishman, E.K.; Kamel, I.R.; Schulick, R.; Zhang, Z.; Topazian, M.; Takahashi, N.; Fletcher, J.; Petersen, G.; et al. Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology 2012, 142, 796–804.
  23. Vege, S.S.; Ziring, B.; Jain, R.; Moayyedi, P.; Adams, M.A.; Dorn, S.D.; Dudley-Brown, S.L.; Flamm, S.L.; Gellad, Z.F.; Gruss, C.B.; et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015, 148, 819–822.
  24. Canto, M.I.; Harinck, F.; Hruban, R.H.; Offerhaus, G.J.; Poley, J.-W.; Kamel, I.; Nio, Y.; Schulick, R.S.; Bassi, C.; Kluijt, I.; et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2012, 62, 339–347.
  25. The European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018, 67, 789–804.
  26. Singhi, A.D.; Koay, E.J.; Chari, S.T.; Maitra, A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology 2019, 156, 2024–2040.
  27. Ben, Q.; Xu, M.; Ning, X.; Liu, J.; Hong, S.; Huang, W.; Zhang, H.; Li, Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur. J. Cancer 2011, 47, 1928–1937.
  28. Munigala, S.; Kanwal, F.; Xian, H.; Scherrer, J.; Agarwal, B. Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis. Clin. Gastroenterol. Hepatol. 2014, 12, 1143–1150.e1.
  29. Tong, G.X.; Geng, Q.-Q.; Chai, J.; Cheng, J.; Chen, P.-L.; Liang, H.; Shen, X.-R.; Wang, D.-B. Association Between Pancreatitis and Subsequent Risk of Pancreatic Cancer: A Systematic Review of Epidemiological Studies. Asian Pac. J. Cancer Prev. 2014, 15, 5029–5034.
  30. Maes, B.; Hastier, P.; Buckley, M.J.; Peten, E.P.; Paolini, O.; Staccini, P.; Conio, M.; Caroli-Bosc, F.-X.; Demarquay, J.F.; Dumas, R.; et al. Extensive aetiological investigations in acute pancreatitis: Results of a 1-year prospective study. Eur. J. Gastroenterol. Hepatol. 1999, 11, 891–896.
  31. Chang, M.C.; Su, C.-H.; Sun, M.-S.; Huang, S.-C.; Chiu, C.-T.; Chen, M.-C.; Lee, K.-T.; Lin, C.-C.; Lin, J.-T. Etiology of acute pancreatitis—A multi-center study in Taiwan. Hepatogastroenterology 2003, 50, 1655–1657.
  32. Gislason, H.; Horn, A.; Hoem, D.; Andrén-Sandberg; Imsland, A.K.; Søreide, O.; Viste, A. Acute Pancreatitis in Bergen, Norway. Scand. J. Surg. 2004, 93, 29–33.
  33. Duell, E.J.; Casella, D.P.; Burk, R.D.; Kelsey, K.T.; Holly, E.A. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 2006, 15, 726–731.
  34. Lowenfels, A.B.; Maisonneuve, P.; Cavallini, G.; Ammann, R.W.; Lankisch, P.G.; Andersen, J.R.; DiMagno, E.P.; Andren-Sandberg, A.; Domellof, L. Pancreatitis and the Risk of Pancreatic Cancer. N. Engl. J. Med. 1993, 328, 1433–1437.
  35. Raimondi, S.; Lowenfels, A.B.; Morselli/labate, A.M.; Maisonneuve, P.; Pezzilli, R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract. Res. Clin. Gastroenterol. 2010, 24, 349–358.
  36. Kirkegård, J.; Mortensen, F.V.; Cronin-Fenton, D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am. J. Gastroenterol. 2017, 112, 1366–1372.
  37. Masamune, A.; Kikuta, K.; Hamada, S.; Nakano, E.; Kume, K.; Inui, A.; Shimizu, T.; Takeyama, Y.; Nio, M.; Shimosegawa, T. Nationwide survey of hereditary pancreatitis in Japan. J. Gastroenterol. 2017, 53, 152–160.
More
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 283
Revisions: 2 times (View History)
Update Date: 08 Jun 2022
1000/1000
Video Production Service